Highlights from The 7th Translational Research Conference on Multiple Myeloma (ESHMM2024)

The 7th Translational Research Conference on Multiple Myeloma (ESHMM2024) took place from October 04-06, 2024, in Mandelieu-La Napoule, France.

The conference was organized by The European School of Haematology, chaired by Hartmut Goldschmidt, Martin Kaiser, and Suzanne Lentzsch.

This event featured leading myeloma experts who presented recent advancements in plasma disorders, covering topics from pathophysiology to diagnosis and treatment. The program emphasized cutting-edge research and encouraged the presentation of unpublished data, allowing ample time for scientific discussions and interactions.

Participants benefited from various informal networking opportunities with experts through:

• Small “Meet the Expert” sessions
• Guided poster walks

The main scientific topics included:

• MGUS
• Smoldering myeloma
• Newly diagnosed fit multiple myeloma
• Newly-diagnosed unfit myeloma patients
• Personalising treatment
• Triplets vs Immunotherapy in Early Lines of Treatment
• Late relapse
• Amyloidosis

Here are some highlights from the conference shared on Social Media:

European School of Haematology (ESH):

“Dr. Rodriguez Otero and Dr. Mailankody present the potential of new targets, specifically GPRC5D, where both BiTes and CAR-Ts show encouraging results. Exciting advancements in the treatment landscape!”

Raj Chakraborty:

“Important iStopMM data on MGUS screening by Sigrun Thorsteinsdottir at ESHMM2024 showing high progression to SMM but not MM in the intervention arms! However, time to MM diagnosis and CRAB presentation slightly low in the intervention arm!

• Will this translate into a longer OS?
• What is the NNT to prevent one CRAB presentation?”

ESH (Haematology):

“Does HDM+ASCT still have a role in frontline MM treatment for all eligible patients?

Mohamad Mohty discusses this important question. Should MRD or high-risk status drive our decision?”

Suzanne Lentzsch:

“ESHMM2024 great presentation and discussion by Sigrun Thorsteinsdottir.

iStopMM in SMM WB-MRI is very sensitive and identifies pt with lesions as active MM very early WB-MRI will change our current assumption of progression rate of SMM to active MM due to earlier detection.”

Martin Kaiser:

“Last day, last session of what has been and is a highly informative and enjoyable ESHMM2024 with Dr. Wechalekar providing updates on AL Amyloidosis in a session with Raj Chakraborty, Suzanne Lentzsch.”

Suzanne Lentzsch:

“Dr. Einsele from University of Würzburg suggests longer interval between BiTEs to allow better T-Cell recovery at ESHMM2024.”

European School of Haematology (ESH):

“Thank you Hartmut Goldschmidt, Martin Kaiser and Suzanne Lentzsch and all our faculty for these great 3 days! Thanks also to all participants for engaging so actively with comments and questions! See you next year in Vienna for the 5th How to Diagnose and Treat Multiple Myeloma (April 3-5, 2025)!”

ESH (Haematology):

“ESHMM2024: And a special thanks to Sina Beer and Abdul-Hamid Bazarbachi, ESH Young Reporters, for lively reporting this conference from a scientific perspective!

Chairs: H. Goldschmidt, Martin Kaiser, Suzanne Lentzsch.”

More posts featuring The European School of Haematology.